{
  "document_id": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement",
  "file_path": "data/CUAD_v1/full_contract_pdf/Part_I/Development/PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement.pdf",
  "text_length": 292143,
  "chunk_count": 392,
  "vector_store_path": "output/vector_stores/PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement",
  "summary": "PROJECTED OR SPECULATIVE FUTURE SALES OF THE PRODUCT, ANY PAYMENT DUE UPON ANY\nUNACHIEVED EVENT UNDER ARTICLE 6 , OR ANY OTHER UNEARNED, SPECULATIVE OR OTHERWISE\nCONTINGENT PAYMENTS PROVIDED FOR IN THIS AGREEMENT. FOR THE AVOIDANCE OF DOUBT, THIS\nSECTION 15.11 IS NOT MEANT TO LIMIT PB\u2019S OBLIGATION TO PAY SFJ THE AMOUNTS SET FORTH IN\nARTICLE 6 OR SECTION 14.2.\n15.12  Cumulative Remedies . Unless expressly set forth in this Agreement, all rights and remedies of the Parties, including\nall rights to payment, rights of termination, rights to injunctive relief, and other rights provided under this Agreement, will be\ncumulative and in addition to all other remedies provided for in this Agreement, in law, and in equity.\n15.13  Relationship of the Parties .\n15.13.1  Independent Contractors . Nothing contained herein will be deemed to create a partnership, joint venture,\n\ntime.\n15.18  Severability . If any provision (or portion thereof) of this Agreement is determined by a court or arbitration to be\nunenforceable as drafted by virtue of the scope, duration, extent, or character of any obligation contained herein, it is the Parties\u2019\nintention that such provision (or portion thereof) will be construed in a manner designed to effectuate the purposes of such\nprovision to the maximum extent enforceable under such Applicable Law. The Parties will enter into whatever amendment to this\nAgreement as may be necessary to effectuate such purposes.\n15.19  Entire Agreement . This Agreement, including all Exhibits hereto and the Disclosure Letter, contains the entire\nunderstanding of the Parties and supersedes, revokes, terminates, and cancels any and all other arrangements, understandings,\nagreements, term sheets,\nSource: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020\n\nduties hereunder\u037e provided, however,  that either Party may assign, sublicense or transfer this Agreement and all of its rights and\nobligations hereunder, in their entirety, to any of its Affiliates or to a successor in connection with the sale or other transfer of all or\nsubstantially all of its business or assets to which this Agreement relates, whether by merger, sale of stock, sale of assets or\notherwise, and\nSource: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020\n\npurchase price and deferred compensation), (b) obligations evidenced by notes, bonds, debentures or similar instruments, (c)\ncapital lease obligations (as such term is understood under GAAP as in effect on\nSource: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
  "parties": "15.13  Relationship of the Parties .\n15.13.1  Independent Contractors . Nothing contained herein will be deemed to create a partnership, joint venture,\nor similar relationship between the Parties, including for tax purposes. Neither Party is the agent, employee, joint venturer, partner,\nfranchisee, or representative of the other Party. Each Party specifically acknowledges that it does not have the authority to, and will\nnot, incur any obligations or responsibilities on behalf of the other Party. Notwithstanding anything to the contrary in this\nAgreement, each Party (and its officers, directors, agents, employees, and members) will not hold themselves out as employees,\nagents,\nSource: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020\n\nPROJECTED OR SPECULATIVE FUTURE SALES OF THE PRODUCT, ANY PAYMENT DUE UPON ANY\nUNACHIEVED EVENT UNDER ARTICLE 6 , OR ANY OTHER UNEARNED, SPECULATIVE OR OTHERWISE\nCONTINGENT PAYMENTS PROVIDED FOR IN THIS AGREEMENT. FOR THE AVOIDANCE OF DOUBT, THIS\nSECTION 15.11 IS NOT MEANT TO LIMIT PB\u2019S OBLIGATION TO PAY SFJ THE AMOUNTS SET FORTH IN\nARTICLE 6 OR SECTION 14.2.\n15.12  Cumulative Remedies . Unless expressly set forth in this Agreement, all rights and remedies of the Parties, including\nall rights to payment, rights of termination, rights to injunctive relief, and other rights provided under this Agreement, will be\ncumulative and in addition to all other remedies provided for in this Agreement, in law, and in equity.\n15.13  Relationship of the Parties .\n15.13.1  Independent Contractors . Nothing contained herein will be deemed to create a partnership, joint venture,\n\nsupplies required for the Clinical Trials or Regulatory Approval with any Person that is either listed on Exhibit C  or is approved in\nadvance by the JDC (each, an \u201c Approved Vendor \u201d). Such Party will be required to enter into a written agreement with each such\nPerson (each, a \u201c Vendor Agreement \u201d) on commercially reasonable and customary terms, consistent with industry standards for\nsimilar agreements and sufficient to enable such Party to comply with its obligations hereunder with respect to the contracted\nactivities, including, but not limited to, the terms pertaining to publications and ownership of Intellectual Property, and treatment of\nConfidential Information.\n2.4.3  Responsibility . For clarity, each Party will remain responsible for all of its obligations under this Agreement,\nnotwithstanding any delegation to an Affiliate or an Approved CRO or any contracting to an Approved Vendor. Each Party shall\n\nfulfilling its obligations under this Agreement.\n13.1.3  Each Party agrees, on behalf of itself and its Affiliates, and its and their respective officers, directors,\nemployees, agents, representatives, consultants, and Permitted Third Parties engaged in connection with the subject matter of this\nAgreement (\u201c Representatives \u201d), that for the performance of its obligations hereunder:\n13.1.3.1  such Party, its Affiliates and its and their respective Representatives shall comply with the Anti-\nCorruption Laws and shall not take any action that will, or would reasonably be expected to, cause the other Party or its Affiliates\nto be in violation of any Anti-Corruption Laws\u037e and\n13.1.3.2  such Party shall promptly provide the other Party with written notice of the following events: (a)\nupon becoming aware of any breach or violation by such Party, its Affiliate or any of its or their respective Representatives of any",
  "key_terms": "PROJECTED OR SPECULATIVE FUTURE SALES OF THE PRODUCT, ANY PAYMENT DUE UPON ANY\nUNACHIEVED EVENT UNDER ARTICLE 6 , OR ANY OTHER UNEARNED, SPECULATIVE OR OTHERWISE\nCONTINGENT PAYMENTS PROVIDED FOR IN THIS AGREEMENT. FOR THE AVOIDANCE OF DOUBT, THIS\nSECTION 15.11 IS NOT MEANT TO LIMIT PB\u2019S OBLIGATION TO PAY SFJ THE AMOUNTS SET FORTH IN\nARTICLE 6 OR SECTION 14.2.\n15.12  Cumulative Remedies . Unless expressly set forth in this Agreement, all rights and remedies of the Parties, including\nall rights to payment, rights of termination, rights to injunctive relief, and other rights provided under this Agreement, will be\ncumulative and in addition to all other remedies provided for in this Agreement, in law, and in equity.\n15.13  Relationship of the Parties .\n15.13.1  Independent Contractors . Nothing contained herein will be deemed to create a partnership, joint venture,\n\npurchase price and deferred compensation), (b) obligations evidenced by notes, bonds, debentures or similar instruments, (c)\ncapital lease obligations (as such term is understood under GAAP as in effect on\nSource: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020\n\n14.4.3.2  solely in the case of termination of this Agreement after payment by SFJ to PB of the Initial\nDevelopment Cost Payment on the Initial Funding Date, but not in the case of expiration of this Agreement, Sections 3.20, 6.1-\n6.7, 7.1-7.7 (in the case of such Sections 7.1-7.7, such provisions shall terminate only after all PB Obligations, other than\ncontingent indemnity obligations, have been paid to SFJ or otherwise satisfied in accordance with this Agreement in full), 14.2 and\n14.3.\nARTICLE 15\nMISCELLANEOUS\n15.1  Relationship with Affiliates . Each Party will be responsible for any breach by its Affiliates of its obligations in\nconnection with this Agreement, and each such Party will remain responsible for any responsibilities that it has delegated to an\nAffiliate as though such Party had performed (or failed to perform) such responsibilities itself.\n15.2  Prior Agreements . The Parties agree on behalf of themselves and their respective Affiliates that any prior\n\nSERVICES, WHETHER LIABILITY IS ASSERTED IN CONTRACT, TORT (INCLUDING NEGLIGENCE AND STRICT\nPRODUCTS LIABILITY), INDEMNITY OR CONTRIBUTION, AND IRRESPECTIVE OF WHETHER THAT PARTY OR\nANY REPRESENTATIVE OF THAT PARTY HAS BEEN ADVISED OF, OR OTHERWISE MIGHT HAVE ANTICIPATED\nTHE POSSIBILITY OF, ANY SUCH LOSS OR DAMAGE. THE PARTIES AGREE THAT THE LIMITATIONS\nSPECIFIED IN THIS SECTION 15.11 WILL APPLY EVEN IF ANY LIMITED REMEDY SPECIFIED IN THIS\nAGREEMENT IS FOUND TO HAVE FAILED OF ITS ESSENTIAL PURPOSE. WITHOUT LIMITING THE\nGENERALITY OF THE FOREGOING, \u201cCONSEQUENTIAL DAMAGES\u201d WILL BE DEEMED TO INCLUDE, AND\nNEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY OR ANY OF SUCH OTHER PARTY\u2019S AFFILIATES,\nREPRESENTATIVES OR STOCKHOLDERS FOR ANY DAMAGES BASED ON OR MEASURED BY LOSS OF\nPROJECTED OR SPECULATIVE FUTURE SALES OF THE PRODUCT, ANY PAYMENT DUE UPON ANY\nUNACHIEVED EVENT UNDER ARTICLE 6 , OR ANY OTHER UNEARNED, SPECULATIVE OR OTHERWISE"
}